Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eritoran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 known ✓ | O00206 | 19/20 | 1.00 |
| ▸ | LY96 known ✓ | Q9Y6Y9 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eritoran SCHEMBL12762848 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL12836754 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL10071635 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL10042165 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL10042160 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL10071018 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL12371609 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL14081112 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL21378839 | 1.00 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL10042156 | 1.00 | TLR4 (1.00) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | EISAI CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | LIPG, FUT6, UGCG | TLR4 94/4885LY96 382/4885 |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | MAN2B2, MAN2A1, MAN2B1 | TLR4 1500/4885LY96 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.